ABCC1 p.Val105Ile
| Predicted by SNAP2: | A: N (57%), C: D (53%), D: D (75%), E: D (71%), F: D (59%), G: D (71%), H: D (75%), I: N (78%), K: D (80%), L: N (61%), M: D (75%), N: D (66%), P: D (71%), Q: D (66%), R: D (75%), S: D (63%), T: D (59%), W: D (75%), Y: D (66%), |
| Predicted by PROVEAN: | A: N, C: D, D: D, E: D, F: D, G: D, H: D, I: N, K: D, L: N, M: N, N: D, P: D, Q: D, R: D, S: D, T: D, W: D, Y: D, |
[switch to compact view]
Comments [show]
None has been submitted yet.
[hide] Clinical pharmacogenetics in pediatric patients. Pharmacogenomics. 2007 Oct;8(10):1403-11. Husain A, Loehle JA, Hein DW
Clinical pharmacogenetics in pediatric patients.
Pharmacogenomics. 2007 Oct;8(10):1403-11., [PMID:17979513]
Abstract [show]
Pediatric pharmacogenetic studies have the potential to improve the quality of medical care for children. The pediatric population presents a unique pharmacogenetic challenge as children have the additional complexity of ontological phenotypes that impact their drug response. Prescribing medications in children has historically been largely empirical, but utilization of pharmacogenetic information will allow pediatricians to gain key information regarding which patients are best suited for a particular therapeutic agent and which patients may be at risk for serious potentially life-threatening complications from standard treatment regimens. Although large, prospective, multisite investigators are still needed, we illustrate selective clinical examples of the pharmacogenetics for treatment of transplantation, asthma, leukemia and attention-deficit hyperactivity disorder in pediatric patients.
Comments [show]
None has been submitted yet.
No. Sentence Comment
62 The lower-activity GSTP1 polymorphism at 1578A>G (GSTP1*B), which results in the amino acid change Val105Ile, is associated with higher etoposide clearance in African-Americans treated with steroids, possibly by inducing ABCB1-medicated drug efflux [19].
X
ABCC1 p.Val105Ile 17979513:62:99
status: NEW